Examining changes in [18 F]FDG and [18 F]FLT uptake in U87-MG glioma xenografts as early response biomarkers to treatment with the dual mTOR1/2 inhibitor AZD8055.

Purpose The mTOR kinase inhibitor AZD8055 inhibits both mTORC1 and mTORC2 leading to disruption of glucose metabolism and proliferation pathways. This study assessed the impact of single and multiple doses of AZD8055 on the uptake of the glucose metabolism marker 2-deoxy-2-[18 F]fluoro-d-glucose ([18 F]FDG) and the proliferation marker 3′-deoxy-3′-[18 F]fluorothymidine ([18 F]FLT) in U87-MG glioma xenografts.